[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 3, 1999

Hormone Replacement Therapy for Secondary Prevention of Coronary Heart Disease—Reply

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;281(9):794-797. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-9-jbk0303

In Reply: In response to Drs Pan and Boal, the rate of aspirin use remained comparable after randomization (eg, 3% had discontinued aspirin in both treatment groups at year 1), and adjusting the relative hazard of CHD events for use of aspirin during the trial did not alter the results. In response to Drs Banks and Beral, endometrial hyperplasia was rare and occurred at about the same rate in both treatment groups over the 4 years; a separate publication will address bleeding and endometrial abnormalities.

First Page Preview View Large
First page PDF preview
First page PDF preview
×